Bp Plc decreased its holdings in shares of Allergan plc (NYSE:AGN) by 38.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,000 shares of the company’s stock after selling 15,000 shares during the quarter. Bp Plc’s holdings in Allergan were worth $3,928,000 at the end of the most recent quarter.
Several other large investors have also modified their holdings of the company. Quadrant Capital Group LLC grew its position in shares of Allergan by 1.4% during the 2nd quarter. Quadrant Capital Group LLC now owns 1,201 shares of the company’s stock worth $235,000 after buying an additional 16 shares during the period. Auxier Asset Management grew its position in shares of Allergan by 0.6% during the 2nd quarter. Auxier Asset Management now owns 8,010 shares of the company’s stock worth $1,947,000 after buying an additional 50 shares during the period. Balentine LLC grew its position in shares of Allergan by 5.6% during the 2nd quarter. Balentine LLC now owns 966 shares of the company’s stock worth $235,000 after buying an additional 51 shares during the period. ELCO Management Co. LLC grew its position in shares of Allergan by 2.9% during the 2nd quarter. ELCO Management Co. LLC now owns 2,132 shares of the company’s stock worth $518,000 after buying an additional 60 shares during the period. Finally, Roberts Glore & Co. Inc. IL grew its position in shares of Allergan by 1.1% during the 2nd quarter. Roberts Glore & Co. Inc. IL now owns 7,103 shares of the company’s stock worth $1,727,000 after buying an additional 75 shares during the period. Institutional investors own 80.23% of the company’s stock.
Allergan plc (NYSE AGN) opened at $162.77 on Friday. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.08 and a current ratio of 2.04. Allergan plc has a one year low of $157.70 and a one year high of $256.80. The firm has a market cap of $54,610.00, a P/E ratio of -13.58, a P/E/G ratio of 1.26 and a beta of 1.19.
The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 28th. Shareholders of record on Wednesday, February 28th will be paid a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a yield of 1.77%. This is a positive change from Allergan’s previous quarterly dividend of $0.70. Allergan’s payout ratio is presently -23.35%.
In related news, Director Christopher J. Coughlin purchased 10,000 shares of the business’s stock in a transaction on Tuesday, December 5th. The shares were purchased at an average price of $163.30 per share, with a total value of $1,633,000.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider William Meury sold 11,807 shares of Allergan stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last ninety days, insiders acquired 17,630 shares of company stock worth $2,890,057. Insiders own 0.36% of the company’s stock.
Several equities research analysts have recently commented on the stock. Bank of America lifted their price target on shares of Allergan from $208.00 to $215.00 and gave the stock a “buy” rating in a research report on Wednesday. Credit Suisse Group lifted their price target on shares of Allergan from $214.00 to $215.00 and gave the stock an “outperform” rating in a research report on Wednesday. Vetr upgraded shares of Allergan from a “hold” rating to a “buy” rating and set a $189.60 price target for the company in a research report on Thursday, February 1st. Leerink Swann lifted their price target on shares of Allergan from $237.00 to $242.00 and gave the stock an “outperform” rating in a research report on Wednesday. Finally, ValuEngine lowered shares of Allergan from a “buy” rating to a “hold” rating in a research note on Friday, February 2nd. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average price target of $227.23.
ILLEGAL ACTIVITY NOTICE: “Bp Plc Has $3.93 Million Stake in Allergan plc (AGN)” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece of content on another site, it was illegally stolen and republished in violation of U.S. & international copyright laws. The legal version of this piece of content can be viewed at https://www.com-unik.info/2018/02/10/bp-plc-has-3-93-million-stake-in-allergan-plc-agn.html.
Allergan Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.